Exogenous Hormone Use Across Diverse Patient Populations With Liver Disease

Description

Jointly hosted by the AASLD Women's Initative Committee and the LGBTQ Task Force, this program includes 3 talks followed by a case presentation (with a question-and-answer period) to address the indications, safety, and efficacy of hormonal therapy across diverse populations with liver disease and liver transplant. Presentation topics include: (1) the safety of gender-affirming hormonal therapy in the context of liver conditions and the risk of liver-related morbidity related to hormonal therapy (ie, DILI) within the growing population of transgender adolescents and adults; (2) the safety and efficacy of estrogen- and progestin-containing contraceptive agents—presented in the context of the US Centers for Disease Control and Prevention 2024 updated contraception guidelines in liver conditions—across the spectrum of liver disease, including post liver transplant; and (3) the safety, efficacy, and potential benefits of testosterone and estrogen therapy in older men and women with liver disease and liver transplant.